Home News

Financial Results Nine month period 2019 - Video

Javier López-Belmonte, Vicepresident and CFO of Laboratorios Farmacéuticos ROVI presents the financial results for the first nine months of 2019.

Mon, 25/11/2019 - 11:12 0 min
Download related document
No votes yet
 
Related
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
ROVI announces the commencement of the assessment process to obtain marketing...
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020
2019 Investor Day presentation
0 min
25/11/2019
ROVI reports operating revenue growth of 24% and EBITDA growth of 83%
Operating revenue increased by 24% to 270.8 million euros in the first nine months of 2019, mainly driven by the strength of the...
5 min
07/11/2019